Neonatal screening in Spain and cost–effectiveness. (September 2015)

• Record Type: Journal Article
• Authors: Serrano-Aguilar, Pedro; Castilla-Rodríguez, Iván; Vallejo-Torres, Laura; Valcárcel-Nazco, Cristina; García-Pérez, Lidia
• Is Part Of: Expert opinion on orphan drugs. Volume 3:Number 9(2015:Sep.)
• Page Start: 971
• Page End: 974
• Publication Date: 2015-09
• Subjects: Orphan drugs -- Periodicals; Rare diseases -- Periodicals; Chemotherapy -- Periodicals; 615.1
• Languages: English
• ISSNs: 2167-8707

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Newborn screening (NBS) programs are subject to inter- and intra-country variations, especially after the introduction of tandem mass spectrometry (MS/MS). Access to MS/MS and variations in interpretation of available evidence seem to explain these differences. Cost considerations have had a minor role on funding decisions given the low direct costs to screen an additional disorder by MS/MS and their low frequency. In order to reduce the wide inter-regional observed variations in NBS in Spain, the Ministry of Health supported by the Spanish Network for Health Technology Assessment developed an evidence-based policy decision process guided by a series of effectiveness and cost–effectiveness reports.</p> </abstract>